CTLA4 and melanoma: During risk factors analysis, they included several parameters not considered in previous studies, revealing that renal cancer, melanoma, CTLA-4 inhibitors, multiple ICI monotherapies, combination ICI therapy, and irAEs in other organs—particularly the liver and endocrine system—were significantly associated with a higher risk of ICI-PI.